Icon (ICLR) Non-Current Deferred Tax Liability (2009 - 2026)
Icon's (ICLR) quarterly Non-Current Deferred Tax Liability came in at $690.3 million in Q2 2026, down 10.93% year-over-year from $775.1 million in Q2 2025, and down 0.58% quarter-over-quarter from $694.3 million in Q1 2026.
Analysis
Icon (ICLR) Non-Current Deferred Tax Liability (2009 - 2026) Analysis & Trends
Icon (ICLR) has reported Non-Current Deferred Tax Liability for 18 consecutive years, with $690.3 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 10.93% year-over-year to $690.3 million in Q2 2026; TTM through Jun 2026 was $690.3 million, a 10.93% decrease from a year earlier, with the FY2025 full-year figure at $714.4 million, down 11.82% from the prior year.
- Non-Current Deferred Tax Liability was $690.3 million for Q2 2026 at Icon, down from $694.3 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $1.1 billion in Q1 2022 and troughed at $690.3 million in Q2 2026.
- A 5-year average of $858.8 million and a median of $856.6 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- The widest YoY moves for Non-Current Deferred Tax Liability: up 7396.16% in 2022, down 20.71% in 2022.
- Over 5 years, Non-Current Deferred Tax Liability stood at $987.9 million in 2022, then fell by 9.07% to $898.3 million in 2023, then dropped by 9.81% to $810.2 million in 2024, then retreated by 11.82% to $714.4 million in 2025, then decreased by 3.37% to $690.3 million in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $690.3 million (Q2 2026), $694.3 million (Q1 2026), and $714.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 690.32 Mn |
| Mar 31, 2026 | 694.32 Mn |
| Dec 31, 2025 | 714.43 Mn |
| Sep 30, 2025 | 744.45 Mn |
| Jun 30, 2025 | 775.07 Mn |
| Mar 31, 2025 | 788.82 Mn |
| Dec 31, 2024 | 810.16 Mn |
| Sep 30, 2024 | 818.33 Mn |
| Jun 30, 2024 | 843.63 Mn |
| Mar 31, 2024 | 869.52 Mn |
| Dec 31, 2023 | 898.31 Mn |
| Sep 30, 2023 | 883.89 Mn |
| Jun 30, 2023 | 934.21 Mn |
| Mar 31, 2023 | 957.02 Mn |
| Dec 31, 2022 | 987.93 Mn |
| Sep 30, 2022 | 974.34 Mn |
| Jun 30, 2022 | 1.02 Bn |
| Mar 31, 2022 | 1.06 Bn |
| Dec 31, 2021 | 1.08 Bn |
| Sep 30, 2021 | 1.23 Bn |